Skip to content
Screener

Zevra Therapeutics, Inc. ZVRA Q4 2025 Annual earnings

Reported March 9, 2026 · After market close

Revenue$34.1MBeat by $6.0M
EPS$1.16Beat by $1.11
Revenue estimate$28.1M
EPS estimate$0.05

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$37.1M
EPS estimate$0.14

Financials

Q4 2025

Income statement

See full
Revenue$34.1M+183%
Gross profit$32.6M+205%
Net income$12.2M+134%
EPS (diluted)$0.19+128%

Balance sheet

See full
Cash & equivalents$62.4M+84.7%
Total debt$63.2M+4.8%
Total equity$154.7M+290%
Total assets$284.7M+59.8%

Cash flow

See full
CapEx-—

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$504.43M+13.3%
Enterprise value$505.23M+7.1%
P/E6.1×—
P/S4.7×-14.1×

Profitability

See full
Gross margin84.5%+15.9pp
Net margin78.2%+42.2pp

Returns & leverage

See full
Return on equity85.7%+50.1pp
Debt / equity0.4×-1.1×
Current ratio5.7×+3.2×

Segments

By product

See full
MIPLYFFA$26.4M+946%
OLPRUVA$300.0K+200%

By segment

See full
Reportable Segment$34.1M+183%

FAQ

When did Zevra Therapeutics, Inc. report Q4 2025 earnings?
Zevra Therapeutics, Inc. (ZVRA) reported Q4 2025 earnings on March 9, 2026 after market close.
What were Zevra Therapeutics, Inc.'s Q4 2025 revenue and EPS?
Zevra Therapeutics, Inc. reported revenue of $34.1M and eps of $1.16 for Q4 2025.
Did Zevra Therapeutics, Inc. beat estimates in Q4 2025?
Revenue beat the consensus estimate of $28.1M by $6.0M. EPS beat the consensus estimate of $0.05 by $1.11.
How did Zevra Therapeutics, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 183.2% from $12.0M a year earlier.
Where can I find Zevra Therapeutics, Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0001434647-26-000009) and the 10-K periodic report (0001434647-26-000011) directly on SEC EDGAR. The filing index links above go to sec.gov.